Perioperative pain, analgesics and cancer-related outcomes: where do we stand?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Van Den Beuken-Van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain Symptom Manage. 51(6), 1070–1090 e1079 (2016).
  MedlineGoogle Scholar
• 2. Graczyk M, Borkowska A, Krajnik M. Why patients are afraid of opioid analgesics: a study on opioid perception in patients with chronic pain. Pol. Arch. Intern. Med. 128(2), 89–97 (2018).
  MedlineGoogle Scholar
• 3. Greer SM, Dalton JA, Carlson J, Youngblood R. Surgical patients' fear of addiction to pain medication: the effect of an educational program for clinicians. Clin. J. Pain 17(2), 157–164 (2001).
  Medline CASGoogle Scholar
• 4. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14(2), 145–161 (2011).
  MedlineGoogle Scholar
• 5. Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet 393(10180), 1558–1568 (2019). • This manuscripts highlits important mechanisms of opioid-induced tolerance, opioiod-induced hyperalgesia and summrizes to the concept of multimodal analgesia.
  MedlineGoogle Scholar
• 6. Zheng J, He J, Wang W et al. The impact of pain and opioids use on survival in cancer patients: results from a population-based cohort study and a meta-analysis. Medicine (Baltimore) 99(9), e19306 (2020).
  MedlineGoogle Scholar
• 7. Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br. J. Anaesth. 113(Suppl. 1), I109–I116 (2014).
  Medline CASGoogle Scholar
• 8. Page GG. The immune-suppressive effects of pain. Adv. Exp. Med. Biol. 521, 117–125 (2003).
  Medline CASGoogle Scholar
• 9. Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. Am. Soc. Clin. Oncol. Educ. Book 39, 24–35 (2019). • Critically summarizes the literature on opioid indications for patients with advanced cancer and their risk for misuse.
  MedlineGoogle Scholar
• 10. WHO Guidelines Approved by the Guidelines Review Committee. In: WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organization, Geneva, Switzlerland (2018).
  Google Scholar
• 11. Calo G, Lambert DG. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. Br. J. Anaesth. 121(5), 1105–1114 (2018).
  Medline CASGoogle Scholar
• 12. Raehal KM, Bohn LM. beta-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb. Exp. Pharmacol. 219, 427–443 (2014).
  Medline CASGoogle Scholar
• 13. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 115(6), 1363–1381 (2011).
  Medline CASGoogle Scholar
• 14. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu. Rev. Biochem. 73, 953–990 (2004).
  Medline CASGoogle Scholar
• 15. Brejchova J, Holan V, Svoboda P. Expression of opioid receptors in cells of the immune system. Int. J. Mol. Sci. 22(1), (2020).
  MedlineGoogle Scholar
• 16. Ondrovics M, Hoelbl-Kovacic A, Fux DA. Opioids: modulators of angiogenesis in wound healing and cancer. Oncotarget 8(15), 25783–25796 (2017).
  MedlineGoogle Scholar
• 17. Ramirez MF, Gorur A, Cata JP. Opioids and cancer prognosis: a summary of the clinical evidence. Neurosci. Lett. 746, 135661 (2021).
  Medline CASGoogle Scholar
• 18. Szczepaniak A, Fichna J, Zielinska M. Opioids in cancer development, progression and metastasis: focus on colorectal cancer. Curr. Treat. Options Oncol. 21(1), 6 (2020).
  MedlineGoogle Scholar
• 19. Renaud AMCaHGaFL. Inhibition by opioids of phagocytosis in peritoneal macrophages. Neuropeptides 18(1), 35–40 (1991).
  MedlineGoogle Scholar
• 20. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol. 121(4), 834–840 (1997).
  Medline CASGoogle Scholar
• 21. Wigmore T, Farquhar-Smith P. Opioids and cancer: friend or foe? Curr Opin Support Palliat Care. 10(2), 109–118 (2016).
  MedlineGoogle Scholar
• 22. Plein LM, Rittner HL. Opioids and the immune system – friend or foe. Br. J. Pharmacol. 175(14), 2717–2725 (2018).
  Medline CASGoogle Scholar
• 23. Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same immunomodulatory properties? a review from animal and human studies. Front. Immunol. 10, 2914 (2019). • Summarizes preclinical and clinical evidence on the effect of opioids in the immune system. It concludes by saying that it is not correct to generalize immunosuppression as a common side effect of all opioid molecules.
  Medline CASGoogle Scholar
• 24. Hutchinson MR, Zhang Y, Shridhar M et al. Evidence that opioids may have Toll-like receptor 4 and MD-2 effects. Brain Behav. Immun. 24(1), 83–95 (2010).
  Medline CASGoogle Scholar
• 25. Mahbuba W, Lambert DG. Opioids and neovascularization; pro or anti? Br. J. Anaesth. 115(6), 821–824 (2015).
  Medline CASGoogle Scholar
• 26. Carli M, Donnini S, Pellegrini C, Coppi E, Bocci G. Opioid receptors beyond pain control: the role in cancer pathology and the debated importance of their pharmacological modulation. Pharmacol. Res. 159, 104938 (2020).
  Medline CASGoogle Scholar
• 27. Cheng S, Guo M, Liu Z et al. Morphine promotes the angiogenesis of postoperative recurrent tumors and metastasis of dormant breast cancer cells. Pharmacology 104(5–6), 276–286 (2019).
  Medline CASGoogle Scholar
• 28. Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ. A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J. Biol. Chem. 273(20), 12402–12406 (1998).
  Medline CASGoogle Scholar
• 29. Liu W, Chen Y, Xu W et al. Fentanyl stimulates tumor angiogenesis via activating multiple pro-angiogenic signaling pathways. Biochem. Biophys. Res. Commun. 532(2), 225–230 (2020).
  Medline CASGoogle Scholar
• 30. Karaman H, Tufek A, Karaman E, Tokgoz O. Opioids inhibit angiogenesis in a chorioallantoic membrane model. Pain Physician 20(2S), SE11–SE21 (2017).
  MedlineGoogle Scholar
• 31. Khabbazi S, Nassar ZD, Goumon Y, Parat MO. Morphine decreases the pro-angiogenic interaction between breast cancer cells and macrophages in vitro. Sci. Rep. 6, 31572 (2016).
  Medline CASGoogle Scholar
• 32. Shi Y, Luo J, Tian J, Zou Q, Wang X. The kappa opioid receptor may be a potential tumor suppressor by regulating angiogenesis in breast cancer. Med. Hypotheses 150, 110568 (2021).
  Medline CASGoogle Scholar
• 33. Mathew B, Lennon FE, Siegler J et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth. Analg. 112(3), 558–567 (2011).
  Medline CASGoogle Scholar
• 34. Gorur A, Patino M, Takahashi H et al. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci. 278, 119541 (2021).
  Medline CASGoogle Scholar
• 35. Li Y, Li G, Tao T et al. The mu-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett. 453, 1–9 (2019).
  Medline CASGoogle Scholar
• 36. Tuerxun H, Cui J. The dual effect of morphine on tumor development. Clin. Transl. Oncol. 21(6), 695–701 (2019).
  Medline CASGoogle Scholar
• 37. Ramirez MF, Gorur A, Cata JP. The role of opioids in cancer progression. Int. Anesthesiol. Clin. 58(2), 57–63 (2020). • Pays special attention to mechanisms by which opioids affect inflammation, immunity, angiogenesis and their direct effects cancer cells.
  Medline CASGoogle Scholar
• 38. Zhang J, Yao N, Tian S. Morphine stimulates migration and growth and alleviates the effects of chemo drugs via AMPK-dependent induction of epithelial-mesenchymal transition in esophageal carcinoma cells. Biol. Pharm. Bull. 43(5), 774–781 (2020).
  Medline CASGoogle Scholar
• 39. Niu DG, Peng F, Zhang W et al. Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget 6(6), 3963–3976 (2015).
  MedlineGoogle Scholar
• 40. Cao LH, Li HT, Lin WQ et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci. Rep. 6, 18706 (2016).
  Medline CASGoogle Scholar
• 41. Naderi J, Samani F, Amooheidari A, Javanmard S, Vahabzadeh G, Vaseghi G. Evaluation of effects of morphine and ionizing radiation in cancer cell lines. J. Cancer Res. Ther. 15(8), 144–152 (2019).
  Google Scholar
• 42. Botticelli A, Cirillo A, Pomati G et al. The role of opioids in cancer response to immunotherapy. J. Transl. Med. 19(1), 119 (2021).
  Medline CASGoogle Scholar
• 43. Zhang HW, Wang F, Zhou YQ, Xu SP, Yu SY, Zhang ZG. Morphine suppresses liver cancer cell tumor properties in vitro and in vivo. Front. Oncol. 11, 666446 (2021).
  MedlineGoogle Scholar
• 44. Zagon IS. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int. J. Oncol. 33(2), 317–323 (2008).
  MedlineGoogle Scholar
• 45. Donahue RN, Mclaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol. Oncol. 122(2), 382–388 (2011).
  Medline CASGoogle Scholar
• 46. Zagon IS, Porterfield NK, Mclaughlin PJ. Opioid growth factor – opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Exp. Biol. Med. (Maywood). 238(6), 589–599 (2013).
  MedlineGoogle Scholar
• 47. Lec PM, Lenis AT, Golla V et al. The role of opioids and their receptors in urological malignancy: a review. J. Urol. 204(6), 1150–1159 (2020).
  MedlineGoogle Scholar
• 48. Zhang H, Sun M, Zhou D et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br. J. Anaesth. 125(5), 722–729 (2020).
  Medline CASGoogle Scholar
• 49. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased mu-opioid receptor expression in metastatic lung cancer. Br. J. Anaesth. 113(Suppl. 1), i103–108 (2014).
  Medline CASGoogle Scholar
• 50. Zhang H, Qu M, Gorur A et al. Association of Mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I–III pancreatic ductal adenocarcinoma. Front. Oncol. 11, 686877 (2021).
  MedlineGoogle Scholar
• 51. Diaz-Cambronero O, Mazzinari G, Giner F et al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel) 12(1), (2020).
  MedlineGoogle Scholar
• 52. Steele GL, Dudek AZ, Gilmore GE et al. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am. J. Clin. Oncol. 43(8), 591–597 (2020).
  Medline CASGoogle Scholar
• 53. Cata JP, Keerty V, Keerty D et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 3(4), 900–908 (2014).
  Medline CASGoogle Scholar
• 54. Wuethrich PY, Thalmann GN, Studer UE, Burkhard FC. Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. PLoS ONE 8(8), e72873 (2013).
  Medline CASGoogle Scholar
• 55. Wu HL, Tai YH, Chang WK et al. Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection?: a retrospective cohort study. Medicine (Baltimore) 98(18), e15442 (2019).
  Medline CASGoogle Scholar
• 56. Cata JP, Zafereo M, Villarreal J et al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. J. Clin. Anesth. 27(8), 672–679 (2015).
  Medline CASGoogle Scholar
• 57. Du KN, Feng L, Newhouse A et al. Effects of intraoperative opioid use on recurrence-free and overall survival in patients with esophageal adenocarcinoma and squamous cell carcinoma. Anesth. Analg. 127(1), 210–216 (2018).
  MedlineGoogle Scholar
• 58. Montagna G, Gupta HV, Hannum M et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br. J. Anaesth. 126(2), 367–376 (2021).
  Medline CASGoogle Scholar
• 59. Sessler DI, Pei L, Huang Y et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet 394(10211), 1807–1815 (2019). •• This randomized controlled trial demostrates that the use of regional anesthesia does not impact cancer progression in women with breast cancer requiring mastectomy.
  MedlineGoogle Scholar
• 60. Rangel FP, Auler JOC Jr, Carmona MJC et al. Opioids and premature biochemical recurrence of prostate cancer: a randomised prospective clinical trial. Br. J. Anaesth. 126(5), 931–939 (2021).
  Medline CASGoogle Scholar
• 61. Du Y-T, Li Y-W, Zhao B-J et al. Long-term survival after combined epidural–general anesthesia or general anesthesia alone: follow-up of a randomized trial. Anesthesiology 135(2), 233–245 (2021).
  Medline CASGoogle Scholar
• 62. Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth. Essays Res. 8(3), 283–290 (2014).
  MedlineGoogle Scholar
• 63. Clark JD. Ketamine for chronic pain: old drug new trick? Anesthesiology 133(1), 13–15 (2020).
  Medline CASGoogle Scholar
• 64. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev. 6, CD003351 (2017).
  MedlineGoogle Scholar
• 65. Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J. Neurosci. 36(44), 11158–11164 (2016).
  Medline CASGoogle Scholar
• 66. Abdollahpour A, Saffarieh E, Zoroufchi BH. A review on the recent application of ketamine in management of anesthesia, pain, and health care. J. Family Med. Prim. Care 9(3), 1317–1324 (2020).
  MedlineGoogle Scholar
• 67. Duan W, Hu J, Liu Y. Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor. Exp. Mol. Pathol. 107, 171–178 (2019).
  Medline CASGoogle Scholar
• 68. Malsy M, Gebhardt K, Gruber M, Wiese C, Graf B, Bundscherer A. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol. 15, 111 (2015).
  MedlineGoogle Scholar
• 69. Zhou X, Zhang P, Luo W et al. Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69. Cancer Med. 7(3), 788–795 (2018).
  Medline CASGoogle Scholar
• 70. Connolly JG, Tan KS, Mastrogiacomo B et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br. J. Anaesth. 127(1), 75–84 (2021).
  Medline CASGoogle Scholar
• 71. Cho JS, Kim NY, Shim J-K, Jun JH, Lee S, Kwak Y-L. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Can. J. Anesth. 68(5), 683–692 (2021).
  Medline CASGoogle Scholar
• 72. Masic D, Liang E, Long C, Sterk EJ, Barbas B, Rech MA. Intravenous lidocaine for acute pain: a systematic review. Pharmacotherapy 38(12), 1250–1259 (2018).
  Medline CASGoogle Scholar
• 73. Dunn LK, Durieux ME. Perioperative use of intravenous lidocaine. Anesthesiology 126(4), 729–737 (2017).
  MedlineGoogle Scholar
• 74. Lee JT, Sanderson CR, Xuan W, Agar M. Lidocaine for cancer pain in adults: a systematic review and meta-analysis. J. Palliat. Med. 22(3), 326–334 (2019).
  MedlineGoogle Scholar
• 75. Cata JP, Ramirez MF, Velasquez JF et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res. 37(9), 4727–4732 (2017).
  Medline CASGoogle Scholar
• 76. Wang H-L, Yan H-D, Liu Y-Y et al. Intraoperative intravenous lidocaine exerts a protective effect on cell-mediated immunity in patients undergoing radical hysterectomy. Mol. Med. Report. 12(5), 7039–7044 (2015).
  Medline CASGoogle Scholar
• 77. Jeon YT, Na H, Ryu H, Chung Y. Modulation of dendritic cell activation and subsequent Th1 cell polarization by lidocaine. PLoS ONE 10(10), e0139845 (2015).
  MedlineGoogle Scholar
• 78. Galos EV, Tat TF, Popa R et al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br. J. Anaesth. 125(5), 712–721 (2020). •• In this manuscript, iv. perioperative lidocaine decreased postoperative expression of NETosis and MMP3, regardless of general anaesthetic technique. This supports the hypothesis that iv. lidocaine during cancer surgery of curative intent might reduce recurrence.
  Medline CASGoogle Scholar
• 79. Carrithers MD, Chatterjee G, Carrithers LM et al. Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. J. Biol. Chem. 284(12), 8114–8126 (2009).
  Medline CASGoogle Scholar
• 80. Zhang L, Hu R, Cheng Y et al. Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A. Cell Prolif. 50(5), (2017).
  Google Scholar
• 81. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer 19(1), 233 (2019).
  MedlineGoogle Scholar
• 82. Gao R, Cao T, Chen H, Cai J, Lei M, Wang Z. Nav1.5-E3 antibody inhibits cancer progression. Transl Cancer Res. 8(1), 44–50 (2019).
  CASGoogle Scholar
• 83. Xing W, Chen DT, Pan JH et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology 126(5), 868–881 (2017).
  Medline CASGoogle Scholar
• 84. Leng T, Lin S, Xiong Z, Lin J. Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. Int. J. Physiol. Pathophysiol. Pharmacol. 9(2), 8–15 (2017).
  Medline CASGoogle Scholar
• 85. Wen J, Li X, Ding Y, Zheng S, Xiao Y. Lidocaine inhibits glioma cell proliferation, migration and invasion by modulating the circEZH2/miR-181b-5p pathway. Neuroreport 32(1), 52–60 (2021).
  Medline CASGoogle Scholar
• 86. D'agostino G, Saporito A, Cecchinato V et al. Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration. Br. J. Anaesth. 121(4), 962–968 (2018).
  MedlineGoogle Scholar
• 87. Gao J, Hu H, Wang X. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling. Cancer Chemother. Pharmacol. 83(6), 1007–1015 (2019).
  Medline CASGoogle Scholar
• 88. Du J, Zhang L, Ma H, Wang Y, Wang P. Lidocaine suppresses cell proliferation and aerobic glycolysis by regulating circHOMER1/miR-138-5p/HEY1 axis in colorectal cancer. Cancer Manag. Res. 12, 5009–5022 (2020).
  Medline CASGoogle Scholar
• 89. Yang X, Zhao L, Li M et al. Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer. Sci. Rep. 8(1), 598 (2018).
  MedlineGoogle Scholar
• 90. Zhang X, Pang W, Liu H, Wang J. Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. J. Cell. Biochem. 120(10), 16533–16542 (2019).
  Medline CASGoogle Scholar
• 91. Zhu J, Han S. Lidocaine inhibits cervical cancer cell proliferation and induces cell apoptosis by modulating the lncRNA-MEG3/miR-421/BTG1 pathway. Am. J. Transl. Res. 11(9), 5404–5416 (2019).
  Medline CASGoogle Scholar
• 92. Ramirez MF, Tran P, Cata JP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg. Anesth. Pain Med. 40(1), 43–48 (2015).
  Medline CASGoogle Scholar
• 93. Galoş EV, Tat T-F, Popa R et al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br. J. Anaesth. 125(5), 712–721 (2020).
  Medline CASGoogle Scholar
• 94. Zhang H, Yang L, Zhu X et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. Br. J. Anaesth. 125(2), 141–148 (2020).
  Medline CASGoogle Scholar
• 95. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiol. 71(7–8), 461–470 (2005).
  Medline CASGoogle Scholar
• 96. Yoshimura N, Sano H, Okamoto M et al. Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg. Today 33(11), 805–811 (2003).
  Medline CASGoogle Scholar
• 97. Huh J, Liepins A, Zielonka J, Andrekopoulos C, Kalyanaraman B, Sorokin A. Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity. Cancer Res. 66(7), 3726–3736 (2006).
  Medline CASGoogle Scholar
• 98. Desai SJ, Prickril B, Rasooly A. Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer. Nutr. Cancer 70(3), 350–375 (2018).
  Medline CASGoogle Scholar
• 99. Kulkarni S, Rader JS, Zhang F et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7(2), 429–434 (2001).
  Medline CASGoogle Scholar
• 100. Soslow RA, Dannenberg AJ, Rush D et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89(12), 2637–2645 (2000).
  Medline CASGoogle Scholar
• 101. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59(17), 4356–4362 (1999).
  Medline CASGoogle Scholar
• 102. Kazberuk A, Zareba I, Palka J, Surazynski A. A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor. Pharmacol. Rep. 72(5), 1152–1160 (2020).
  Medline CASGoogle Scholar
• 103. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8(20), 3267–3273 (2009).
  Medline CASGoogle Scholar
• 104. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 15, 106 (2015).
  MedlineGoogle Scholar
• 105. Huang XZ, Gao P, Sun JX et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control 26(4), 589–600 (2015).
  MedlineGoogle Scholar
• 106. Johnson CC, Jankowski M, Rolnick S, Yood MU, Alford SH. Influence of NSAID use among colorectal cancer survivors on cancer outcomes. Am. J. Clin. Oncol. 40(4), 370–374 (2017).
  Medline CASGoogle Scholar
• 107. Iovoli AJ, Hermann GM, Ma SJ et al. Association of nonsteroidal anti-inflammatory drug use with survival in patients with squamous cell carcinoma of the head and neck treated with chemoradiation therapy. JAMA Netw Open. 3(6), e207199 (2020).
  MedlineGoogle Scholar
• 108. Choi JE, Villarreal J, Lasala J et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 4(6), 825–833 (2015).
  Medline CASGoogle Scholar
• 109. Forget P, Tombal B, Scholtes JL et al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? Eur. J. Anaesthesiol. 28(12), 830–835 (2011).
  Medline CASGoogle Scholar
• 110. Zhao X, Xu Z, Li H. NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis. Sci. Rep. 7(1), 1875 (2017).
  MedlineGoogle Scholar
• 111. Magee DJ, Jhanji S, Poulogiannis G, Farquhar-Smith P, Brown MRD. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. Br. J. Anaesth. 123(2), e412–e423 (2019).
  Medline CASGoogle Scholar
• 112. Cata JP, Guerra CE, Chang GJ, Gottumukkala V, Joshi GP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. Br. J. Anaesth. 119(4), 750–764 (2017).
  Medline CASGoogle Scholar
• 113. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br. J. Anaesth. 113(Suppl. 1), i82–87 (2014).
  Medline CASGoogle Scholar
• 114. Forget P, Machiels J-P, Coulie P et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann. Surg. Oncol. 20, 650–660 (2013).
  MedlineGoogle Scholar
• 115. Grahn O, Lundin M, Lydrup ML, Angenete E, Rutegård M. Postoperative non-steroidal anti-inflammatory drug use and oncological outcomes of rectal cancer. BJS Open 5(1), (2021).
  MedlineGoogle Scholar
• 116. Forget P, Vandenhende J, Berliere M et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth. Analg. 110(6), 1630–1635 (2010).
  Medline CASGoogle Scholar
• 117. Yang EV, Sood AK, Chen M et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 66(21), 10357–10364 (2006).
  Medline CASGoogle Scholar
• 118. Lee BM, Rodriguez A, Mena G et al. Platelet-to-lymphocyte ratio and use of NSAIDs during the perioperative period as prognostic indicators in patients with NSCLC undergoing surgery. Cancer Control 23(3), 284–294 (2016).
  MedlineGoogle Scholar
• 119. De Castro Araujo BL, De Oliveira JL, Rezende JFN, Noguera WS, De Melo AC, Thuler LCS. Impact of non-steroidal anti-inflammatory drugs on recurrence and survival after melanoma surgery: a cohort study. Cancer Invest. 38(7), 415–423 (2020).
  MedlineGoogle Scholar
• 120. Wang RD, Zhu JY, Zhu Y, Ge YS, Xu GL, Jia WD. Perioperative analgesia with parecoxib sodium improves postoperative pain and immune function in patients undergoing hepatectomy for hepatocellular carcinoma. J. Eval. Clin. Pract. 26(3), 992–1000 (2019).
  MedlineGoogle Scholar
• 121. Forget P, Bouche G et al. Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE 14(12), e0225748 (2019).
  Medline CASGoogle Scholar
• 122. Meyerhardt JA, Shi Q, Fuchs CS et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer. JAMA 325(13), (2021).
  MedlineGoogle Scholar
• 123. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol. Res. Perspect. 4(2), e00205 (2016).
  MedlineGoogle Scholar
• 124. Dethloff L, Barr B, Bestervelt L et al. Gabapentin-induced mitogenic activity in rat pancreatic acinar cells. Toxicol. Sci. 55(1), 52–59 (2000).
  Medline CASGoogle Scholar
• 125. Bugan I, Karagoz Z, Altun S, Djamgoz MB. Gabapentin, an analgesic used against cancer-associated neuropathic pain: effects on prostate cancer progression in an in vivo rat model. Basic Clin. Pharmacol. Toxicol. 118(3), 200–207 (2016).
  Medline CASGoogle Scholar
• 126. Ding Y, Robbins J, Fraser SP, Grimes JA, Djamgoz MB. Comparative studies of intracellular Ca2+ in strongly and weakly metastatic rat prostate cancer cell lines. Int. J. Biochem. Cell Biol. 38(3), 366–375 (2006).
  Medline CASGoogle Scholar
• 127. Irizarry MC, Webb DJ, Boudiaf N et al. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol. Drug Saf. 21(2), 214–225 (2012).
  MedlineGoogle Scholar
• 128. Zhao Y, He J, Yu N, Jia C, Wang S. Mechanisms of dexmedetomidine in neuropathic pain. Front. Neurosci. 14, 330 (2020).
  MedlineGoogle Scholar
• 129. Brown EN, Pavone KJ, Naranjo M. Multimodal general anesthesia: theory and practice. Anesth. Analg. 127(5), 1246–1258 (2018).
  MedlineGoogle Scholar
• 130. Lavon H, Matzner P, Benbenishty A et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br. J. Anaesth. 120(1), 188–196 (2018).
  Medline CASGoogle Scholar
• 131. Wang C, Datoo T, Zhao H et al. Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo. Anesthesiology 129(5), 1000–1014 (2018).
  Medline CASGoogle Scholar
• 132. Castillo LF, Rivero EM, Goffin V, Luthy IA. Alpha2-adrenoceptor agonists trigger prolactin signaling in breast cancer cells. Cell. Signal. 34, 76–85 (2017).
  Medline CASGoogle Scholar
• 133. Chen P, Luo X, Dai G et al. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp. Mol. Med. 52(7), 1062–1074 (2020).
  Medline CASGoogle Scholar
• 134. Tian H, Hou L, Xiong Y, Cheng Q. Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/beta-catenin signaling pathway. Cell Cycle 20(8), 765–780 (2021).
  Medline CASGoogle Scholar
• 135. Zhang P, He H, Bai Y, Liu W, Huang L. Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis. Anticancer Drugs 31(7), 693–701 (2020).
  Medline CASGoogle Scholar
• 136. Dong W, Chen MH, Yang YH et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 21(15), 3510–3515 (2017).
  Medline CASGoogle Scholar
• 137. Wang Y, Xu X, Liu H, Ji F. Effects of dexmedetomidine on patients undergoing radical gastrectomy. J. Surg. Res. 194(1), 147–153 (2015).
  Medline CASGoogle Scholar
• 138. Liu Y, Sun J, Wu T et al. Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: a prospective randomized controlled trial. Cancer Med. 8(18), 7603–7612 (2019).
  Medline CASGoogle Scholar
• 139. Cata JP, Singh V, Lee BM et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J. Anaesthesiol. Clin. Pharmacol. 33(3), 317–323 (2017).
  MedlineGoogle Scholar